Who has been buying Samik Pharmaceutical stock?

1 distinct insiders have filed 0 disclosed insider purchases in Samik Pharmaceutical (014950), most recently on 2026-06-30. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Samik Pharmaceutical have?

Samik Pharmaceutical has 0 buy-side and 13 sell-side disclosures on record, covering ₩254M ($177K) in total reported value, spanning 2025-10-27 to 2026-06-30.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Samik Pharmaceutical 014950

Company

삼익제약Samik Pharmaceutical

Insiders

Buys

Total Value

₩254M ($177K)

Avg Return

+4.70%

Last Filing

2026-06-30

Samik Pharmaceutical (014950) has 0 disclosed insider purchases and 13 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩254M ($177K) in reported transaction value. The earliest filing StockDrifts holds for Samik Pharmaceutical is dated 2025-10-27; the most recent is 2026-06-30. Across these filings the average return since disclosure is +4.70%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-09-17	SELL	Market Sell	권영이 Kwon Young-i	Each CEO	-20.0K	₩10,290	+11.2%	₩220M ($153K)
2026-06-30	BUY	주식매수선택권	권영이 Kwon Young-i	Each CEO	60.0K	₩6,470	-35.9%	₩388M ($270K)
2026-06-05	SELL	Market Sell	권영이 Kwon Young-i	Each CEO	-15.0K	-	-	-
2026-06-04	SELL	Market Sell	권영이 Kwon Young-i	Each CEO	-1.0K	₩6,060	-1.3%	₩6M ($4K)
2026-06-04	SELL	Market Sell	권영이 Kwon Young-i	Each CEO	-10	₩6,060	-1.3%	₩61K ($42)
2026-06-04	SELL	Market Sell	권영이 Kwon Young-i	Each CEO	-302	₩6,060	-1.3%	₩2M ($1K)
2026-06-04	SELL	Market Sell	권영이 Kwon Young-i	Each CEO	-1.0K	₩6,060	-1.3%	₩6M ($4K)
2026-06-04	SELL	Market Sell	권영이 Kwon Young-i	Each CEO	-1.0K	₩6,060	-1.3%	₩6M ($4K)
2026-05-27	SELL	Market Sell	권영이 Kwon Young-i	Each CEO	-11.9K	₩6,960	+11.8%	₩83M ($58K)
2026-05-27	SELL	Market Sell	권영이 Kwon Young-i	Each CEO	-68	₩6,960	+11.8%	₩473K ($329)
2026-05-27	SELL	Market Sell	권영이 Kwon Young-i	Each CEO	-1.6K	₩6,960	+11.8%	₩11M ($8K)
2026-05-27	SELL	Market Sell	권영이 Kwon Young-i	Each CEO	-5.0K	₩6,960	+11.8%	₩35M ($24K)
2026-05-18	SELL	Market Sell	권영이 Kwon Young-i	Each CEO	-683	₩7,550	+2.9%	₩5M ($4K)
2026-05-18	SELL	Market Sell	권영이 Kwon Young-i	Each CEO	-2.4K	₩7,550	+2.9%	₩18M ($13K)
2026-05-14	SELL	Market Sell	권영이 Kwon Young-i	Each CEO	-10.0K	₩8,150	+10.1%	₩82M ($57K)
2026-03-26	BUY	주식매수선택권	권영이 Kwon Young-i	Each CEO	25.0K	₩10,960	+0.0%	₩274M ($190K)
2026-01-12	BUY	신규등록	변길영 Byun Gil-young	Managing Director	2.0K	₩18,210	-20.8%	₩36M ($25K)
2026-01-12	BUY	신규등록	곽경희 Kwak Kyung-hee	moving	2.0K	₩18,210	-20.8%	₩36M ($25K)
2026-01-12	BUY	신규등록	황준일 Hwang Jun-il	Assistant Managing Director	5.5K	₩18,210	-20.8%	₩100M ($70K)
2025-12-30	BUY	주식매수선택권	권영이 Kwon Young-i	Each CEO	25.0K	₩13,970	+3.3%	₩349M ($243K)
2025-10-27	BUY	신규상장	이용석 Lee Yong-seok	vice president	1.0M	₩9,720	+48.5%	₩9.7B ($6.8M)
2025-10-27	BUY	신규상장	김선욱 Seonwook Kim	-	932.0K	₩9,720	+48.5%	₩9.1B ($6.3M)
2025-10-27	BUY	신규상장	이충환 Choonghwan Lee	CEO	2.0M	₩9,720	+48.5%	₩19.4B ($13.5M)
2025-10-27	BUY	신규상장	이세영 Seyoung Lee	Chairman	1.1M	₩9,720	+48.5%	₩10.4B ($7.2M)

Frequently asked questions

Who has been buying Samik Pharmaceutical stock?: 1 distinct insiders have filed 0 disclosed insider purchases in Samik Pharmaceutical (014950), most recently on 2026-06-30. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Samik Pharmaceutical have?: Samik Pharmaceutical has 0 buy-side and 13 sell-side disclosures on record, covering ₩254M ($177K) in total reported value, spanning 2025-10-27 to 2026-06-30.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.